Cheng T L, Cantrill L C, Schindeler A, Little D G
Orthopaedic Research and Biotechnology Unit, Children's Hospital at Westmead, Sydney, NSW, Australia.
Discipline of Child and Adolescent Health, Sydney Medical School, University of Sydney, Sydney, NSW, Australia.
J Child Orthop. 2019 Oct 1;13(5):543-550. doi: 10.1302/1863-2548.13.190119.
Surgical interventions are routinely performed on children with osteogenesis imperfecta (OI) to stabilize long bones, often post fracture. We speculated that a combination of intramedullary reaming and intraosseous injection of recombinant bone morphogenetic protein-2 (BMP-2) could enhance periosteal ossification and ultimately cortical thickness and strength. This approach was conceptually tested in a preclinical model of genetic bone fragility.
Six experimental groups were tested including no treatment, intramedullary reaming, and reaming with 5 µg BMP-2 injection performed in the tibiae of both wild type (WT) and Col1a2 (OI, Amish mutation) mice. Bone formation was examined at a two-week time point in ex vivo specimens by micro-computed tomography (microCT) analysis and histomorphometry with a dynamic bone label.
MicroCT data illustrated increases in tibial cortical thickness with intramedullary reaming alone (Saline) and reaming plus BMP-2 injection (BMP-2) compared to no intervention controls. In the OI mice, the periosteal bone increase was not statistically significant with Saline but there was an increase of +192% (p = 0.053) with BMP-2 injection. Dynamic histomorphometry on calcein label was used to quantify new woven bone formation; while BMP-2 induced greater bone formation than Saline, the anabolic response was blunted overall in the OI groups.
These data indicate that targeting the intramedullary compartment via reaming and intraosseous BMP-2 delivery can lead to gains in cortical bone parameters. It is suggested that the next step is to validate safety and functional improvements in a clinical OI setting.
对于成骨不全(OI)患儿,通常会在骨折后对其长骨进行手术干预以实现稳定。我们推测,髓内扩髓联合骨内注射重组骨形态发生蛋白-2(BMP-2)可增强骨膜成骨,并最终增加皮质骨厚度和强度。该方法在遗传性骨脆性的临床前模型中进行了概念验证。
对六个实验组进行了测试,包括不治疗、髓内扩髓,以及在野生型(WT)和Col1a2(OI,阿米什突变)小鼠的胫骨中进行扩髓并注射5μg BMP-2。在两周时间点,通过微计算机断层扫描(microCT)分析和动态骨标记的组织形态计量学对离体标本中的骨形成进行检查。
与未干预对照组相比,microCT数据表明,单纯髓内扩髓(生理盐水)以及扩髓加BMP-2注射(BMP-2)均可增加胫骨皮质厚度。在OI小鼠中,生理盐水组的骨膜骨增加无统计学意义,但BMP-2注射组增加了192%(p = 0.053)。使用钙黄绿素标记的动态组织形态计量学来量化新编织骨的形成;虽然BMP-2诱导的骨形成比生理盐水组更多,但OI组的合成代谢反应总体上减弱。
这些数据表明,通过扩髓和骨内递送BMP-2靶向髓内腔可增加皮质骨参数。建议下一步在OI临床环境中验证安全性和功能改善情况。